# US 2016/0250148 A1 · Tripulse release stimulant formulations

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250148 A1
- Document ID: US20160250148A1
- Status: Published application
- Kind: A1
- Application number: 15/054,934
- Filed: 2016-02-26
- Published: 2016-09-01
- Earliest claimed: 2015-02-27
- Assignees: Cingulate Therapeutics LLC
- Applicants: Cingulate Therapeutics LLC
- Inventors: Matthew Brams; Raul Silva; Arthur Straughn
- Web page: https://patentgrep.com/patent/US20160250148A1

## CPC

- A61K 9/209: {containing drug in at least two layers or in the core and in at least one outer layer}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 31/137: Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine {or methadone}
- A61K 31/4458: only substituted in position 2, e.g. methylphenidate
- A61P 25/14: for treating abnormal movements, e.g. chorea, dyskinesia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A single dosage form that delivers a tripulse (i.e., three pulses) release profile is provided. The dosage form includes at least three dosage units inside the final dosage form. By providing a single dosage form with multiple dosage units, the dosing frequency is decreased since precise blood levels of the active over a prolonged time period are controlled and achieved.

## Claims

### Claim 1

A pulsatile release dosage form for oral administration of a stimulant, comprising
(a) a first dosage unit comprising a first stimulant dose that is released substantially immediately following oral administration of the dosage form to a patient;
(b) a second dosage unit comprising a second stimulant dose, wherein the second stimulant dose is delayed until about 2 to about 5 hours following administration of the dosage form to a patient; and
(c) a third dosage unit comprising a third stimulant dose, wherein the third stimulant dose is delayed until about 5 to about 9 hours following oral administration of the dosage form to a patient;
wherein the stimulant is methylphenidate or amphetamine, or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The dosage form of claim 1, wherein the first dosage unit releases about 30% to about 40% of the total stimulant in the dosage form.

### Claim 3 (depends on 1)

The dosage form of claim 1, wherein the first dosage unit releases about 35% to about 40% of the total stimulant in the dosage form.

### Claim 4 (depends on 1)

The dosage form of claim 1, wherein the second dosage unit releases about 40% to about 50% of the total stimulant in the dosage form.

### Claim 5 (depends on 1)

The dosage form of claim 1, wherein the second dosage unit releases about 45% to about 50% of the total stimulant in the dosage form.

### Claim 6 (depends on 1)

The dosage form of claim 1, wherein the third dosage unit releases about 10% to about 20% of the total stimulant in the dosage form.

### Claim 7 (depends on 1)

The dosage form of claim 1, wherein the third dosage unit releases about 15% to about 20% of the total stimulant in the dosage form.

### Claim 8 (depends on 1)

The dosage form of claim 1, wherein the second stimulant dose is delayed until about 3 to about 4 hours following administration of the dosage form to a patient

### Claim 9 (depends on 1)

The dosage form of claim 1, wherein the third stimulant dose is delayed until about 6 to about 8 hours following oral administration of the dosage form to a patient.

### Claim 10 (depends on 1)

The dosage form of claim 1, wherein the dosage form is a tablet.

### Claim 11 (depends on 1)

The dosage form of claim 1, wherein the second stimulant dose is released over a time period of from about 45 to about 90 minutes.

### Claim 12 (depends on 1)

The dosage form of claim 1, wherein the second stimulant dose is released over a time period of from about 60 minutes to about 90 minutes.

### Claim 13 (depends on 1)

The dosage form of claim 1, wherein the first, second and third dosage units each comprise a core that is at least partially surrounded by an erosion matrix.

### Claim 14

A method of treatment of a disorder, condition or disease for which a stimulant is generally indicated, the method comprising the steps of
administering a pharmaceutically acceptable amount of a once-daily dosage form, the dosage form comprising
(a) a first dosage unit comprising a first stimulant dose that is released substantially immediately following oral administration of the dosage form to a patient;
(b) a second dosage unit comprising a second stimulant dose, wherein the second stimulant dose is delayed until about 2 to about 5 hours following administration of the dosage form to a patient; and
(c) a third dosage unit comprising a third stimulant dose, wherein the third stimulant dose is delayed until about 5 to about 9 hours following oral administration of the dosage form to a patient;
wherein the stimulant is methylphenidate or amphetamine, or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 14)

The method of claim 14, wherein the disorder, condition or disease is ADHD.
